James D Neaton

发表

Network meta-analysis of randomized clinical trials: Reporting the proper summaries

Bradley P Carlin, Haitao Chu, Lei Nie, 2014, Clinical trials.

Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk for AIDS and Non-AIDS Diseases

David Krason, Keith Henry, James D Neaton, 2008, Journal of acquired immune deficiency syndromes.

ZIP-code-based versus tract-based income measures as long-term risk-adjusted mortality predictors.

Lynn E Eberly, Avis J. Thomas, George Davey Smith, 2006, American journal of epidemiology.

Designs for mechanical circulatory support device studies.

Annetine Gelijns, Sharon-Lise Normand, James D Neaton, 2007, Journal of cardiac failure.

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Peter Sleight, Janet Wittes, James D Neaton, 2003, JAMA.

Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.

John G F Cleland, Stefan D Anker, Barry Greenberg, 2020, JACC. Heart failure.

Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.

Lynn E Eberly, Gabriele Riccardi, Jeremiah Stamler, 2004, Archives of internal medicine.

Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial.

James D Neaton, R. Prineas, J. Neaton, 2006, Journal of the American Society of Nephrology : JASN.

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Rebecca Hoh, Peter Bacchetti, Matthew C Strain, 2013, The Journal of infectious diseases.

Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men.

Hanna E Bloomfield, James D Neaton, H. Bloomfield, 2008, The American journal of cardiology.

Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health

Abdel Babiker, Janet Darbyshire, James D Neaton, 2010, Clinical trials.

Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.

Jacques Fellay, Amalio Telenti, Huldrych F Günthard, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Monitoring the quality of conduct of clinical trials: a survey of current practices

James D Neaton, J. Neaton, J. Kramer, 2011, Clinical trials.

Effect estimates in randomized trials and observational studies: comparing apples with apples.

Haitao Chu, Kholoud Porter, Stephen R Cole, 2019, American journal of epidemiology.

Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection

Lewis H Kuller, H. Clifford Lane, Bruno Ledergerber, 2008, PLoS medicine.

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation

Haitao Chu, Stephen R Cole, Roger Logan, 2016, AIDS.

Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Handan Wand, Sean Emery, Daniel E Nixon, 2011, The Journal of infectious diseases.

Key issues in end point selection for heart failure trials: composite end points.

Gerry Gray, James D Neaton, Bram D. Zuckerman, 2005, Journal of cardiac failure.

Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials

Birgit Grund, James D Neaton, J. Neaton, 2008, Current opinion in HIV and AIDS.